Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
PQA-18 is an inhibitor of p21-activated kinase 2 (PAK2; IC50 = 10 nM), an immunosuppressant, and a derivative of Ppc-1 (Item No. 42352).1 It inhibits the production of IL-2 induced by concanavalin A (Item No. 14951) in Jurkat T cells (IC50 = 400 nM). Topical application of PQA-18 (0.1%) decreases disease severity, serum IgE levels, and skin thickness in the NC/Nga mouse model of atopic dermatitis. It also reduces cutaneous nerve fiber density in NC/Nga mice when applied topically at 0.05%.2 PQA-18 (4 mg/kg) increases graft survival rate in a rat model of small intestine transplant.3
WARNING This product is not for human or veterinary use.
1. Prenylated quinolinecarboxylic acid derivative suppresses immune response through inhibition of PAK2. Biochem Pharmacol. 105, 55-65 (2016).
2. Prenylated quinolinecarboxylic acid compound-
3. The effect of a novel immunosuppressive drug, a PAK-